Here are the 10-K annual reports from Whitehawk Therapeutics, Inc. (WHWK) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow WHWK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WHWK filings page.
Whitehawk Therapeutics is refocusing as a clinical-stage oncology company built around three next-generation antibody-drug conjugates licensed from WuXi Biologics. Lead candidates HWK-007 and HWK-016 have cleared U.S. INDs, with Phase 1 trials recruiting and data readouts expected in the first half of 2027. An IND for HWK-206 is planned for mid-2026.
The company exited its prior FYARRO Business, selling 100% of the FYARRO operating subsidiary to KAKEN for $102.4 million, and no longer commercializes FYARRO. FYARRO generated net product sales of $7.1 million in 2025 and $26.0 million in 2024. Management believes existing cash, cash equivalents and short-term investments can fund planned operations into 2028.